Investigational drug · Phase 2
RNK08954
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumor Cancer, PDAC, KRAS G12D Mutations.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
5
Any phase or sponsor naming "RNK08954"
First trial start
2025
Oct 14, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RNK08954", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor Cancer
- PDAC
- KRAS G12D Mutations
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Advanced Gynecologic Malignancies
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "RNK08954" as an intervention, largest first.
Ranok Therapeutics (Hangzhou) Co., Ltd.Industry
NCT06667544 · 152 participants (planned) · Start Nov 8, 2024 · Primary completion Dec 2026
Drug: RNK08954-01 · For: KRAS G12D Mutation
Sites: Nanning, China; Zhengzhou, China; Wuhan, China · 6 sites in all
- To Evaluate the Safety and Efficacy of RNK08954 in Patients With Advanced Gynecological Tumors.Not yet recruiting
Ranok Therapuetics Co. Ltd.Industry
NCT07848893 · 120 participants (planned) · Start Sep 15, 2026 · Primary completion Aug 31, 2028
Drug: RNK08954 · For: Advanced Gynecologic Malignancies
Sites: Shanghai, China
InxMed (Shanghai) Co., Ltd.Industry
NCT07441174 · 92 participants (planned) · Start Feb 28, 2026 · Primary completion Feb 28, 2031
Drug: IN10018 in combination with RNK08954 · For: Solid Tumor Cancer; PDAC
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 14 sites in all
Ranok Therapeutics (Hangzhou) Co., Ltd.Industry
NCT07303465 · 60 participants (planned) · Start Oct 14, 2025 · Primary completion Nov 30, 2026
Drug: RNK08954 · For: KRAS G12D Mutations; Pancreatic Ductal Adenocarcinoma (PDAC)
Sites: Nanjing, China; Shanghai, China
- A Study to Evaluate the Food Effect on RNK08954 in Healthy Participants, and the Mass Balance Study of [14C]RNK08954 in Healthy Adult Male SubjectsNot yet recruiting
Ranok Therapeutics (Hangzhou) Co., Ltd.Industry
NCT07334262 · 24 participants (planned) · Start Dec 31, 2025 · Primary completion Dec 1, 2026
Drug: RNK08954 · For: Food Effect; Mass Balance
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor.
Xie L, Xu C, Si H, et al. · Cancer Discov 2026
Also in development for Solid Tumor Cancer
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- AD1208Phase 21 trial
Avelos Therapeutics Inc. · Solid Tumor, Adult, Tumor, Solid, Solid Tumor
- AVZO-103Phase 21 trial
Avenzo Therapeutics, Inc. · Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors
- AVZO-1418Phase 21 trial
Avenzo Therapeutics, Inc. · Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.